SAVA Healthcare

What SAVA Healthcare does

SAVA Healthcare Limited is an Indian pharmaceutical manufacturer and CDMO founded in 2003 and headquartered in Pune, with operations across 6 countries and exports to more than 35 countries. The company's commercial model rests on four verticals: a CDMO/Contract Manufacturing for Bharat (CMB) business serving Indian and global pharma majors (including Cipla, Dr. Reddy's, and Lupin); an International Business exporting respiratory, oral solid, and topical products through 350+ registrations across 5 continents; the SAVAVET division covering companion and farm animal pharmaceuticals; and SAVA Herbals, a recently launched B2C Ayurvedic/herbal wellness line with 30 SKUs.

The company's core technology centers on nasal and pulmonary drug delivery, operating a cGMP, EU-GMP, WHO-GMP, TGA, PIC/s, and Health Canada certified manufacturing facility in Surendranagar, Gujarat with 45 million nasal spray units of annual capacity, plus capabilities across dry powder inhalers (manufactured under controlled humidity with 1-5 µm particle size precision), oral solids, capsules, dry powders for oral suspension, and topical dosage forms. A DSIR-approved R&D center in Pune with 30 scientists has developed over 325 in-house formulations, including generic equivalents of major respiratory brands (Advair, Foradil, Spiriva) and a novel combination nasal spray that received DCGI approval in June 2025. A Rs 300 crore greenfield, EUGMP/USFDA-compliant plant under construction in Indore is targeted for phased completion through 2026 and will add capacity of 30 million vials and 2,351.3 million total SKUs annually.

SAVA generates revenue through three primary channels: B2B contract manufacturing and formulation development services on a quote-based professional services model; one-time product sales of branded respiratory, veterinary, and herbal SKUs through distributor networks and direct channels; and international exports to partners such as JAMP Pharma (Canada) and MoviHealth (Ukraine). Customer segments span large Indian and multinational pharmaceutical companies (enterprise CDMO clients), veterinarians and pet owners (SAVAVET), health-conscious consumers (SAVA Herbals), and healthcare providers in regulated and emerging markets. The company is publicly listed in India, founder-led under Chairman Vinod R. Jadhav and Managing Director Dinesh Kapoor, with no disclosed institutional PE/VC ownership.

Name

SAVA Healthcare

Legal name

SAVA Healthcare Limited

Website

https://savaglobal.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SAVA Healthcare Limited is a Pune-based Indian pharmaceutical manufacturer and CDMO specializing in nasal sprays, dry powder inhalers, and oral solids, exporting to 35+ countries and serving pharma majors (Cipla, Lupin, Dr. Reddy's) plus veterinary and Ayurvedic consumer markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industries

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract pharmaceutical manufacturing
• Nasal drug delivery
• Dry powder inhalers
• Veterinary pharmaceuticals
• Herbal consumer products

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research & Manufacturing Services (CRAMS): Provides end-to-end pharmaceutical contract manufacturing services from formulation development to commercial-scale manufacturing. Services include preclinical and clinical research services, technical transfer, P2P & Loan License manufacturing, and tender/institutional business through global business associates.
2. International Business Exports: Export of pharmaceutical products to international markets including Canada, Ukraine, CIS countries, Asia, Africa, and French West Africa. Products include respiratory (nasal sprays, dry powder inhalers), oral solids, topicals, and veterinary products. Approximately 350 quality product registrations across 5 continents.
3. SAVA Herbals Consumer Products: B2C herbal formulations business launched recently with 30 SKUs including Ayurvedic nutraceuticals, herbal teas, topical formulations. Shifted from B2B to B2C distribution model targeting consumers through digital channels.
4. SAVAVET Veterinary Products: Veterinary pharmaceutical division covering companion animals (dogs, cats) and farm animals. Products include dermatology portfolio, ear care (EARWORKS), dental care (ORAPET), anti-fungal therapy (FELINTRA), and partnership with Dermoscent for pet dermo-cosmetic products.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

SAVA Healthcare is a pharmaceutical manufacturer that produces nasal drug delivery products, dry powder inhalers, oral solid dosage forms, and topical formulations. It operates a contract development and manufacturing (CDMO) business serving leading pharmaceutical companies, an international export business, a veterinary pharmaceutical line (SAVAVET), and a consumer herbal products range (SAVA Herbals).

Product overview

SAVA Healthcare Limited is a pharmaceutical company organized into four key business verticals: International Business (global distribution of human and veterinary pharmaceuticals), CDMO/CRAMS (Contract Development and Manufacturing Organization services), SAVAVET (companion and farm animal healthcare), and SAVA Herbals (herbal/Ayurvedic formulations). The product portfolio centers on nasal drug delivery platforms (nasal sprays and drops for allergic rhinitis, congestion, and respiratory conditions), dry powder inhalers (DPIs for asthma and COPD including FLUTIAIR-S series, FORMEZON, TIODORA), oral solids (tablets in various formulations), topical preparations (creams, gels, ointments), and veterinary products (CARODYL, FELINTRA, EARWORKS, ORAPET). The company operates EU-GMP/WHO-GMP compliant manufacturing facilities in Gujarat's Surendranagar with annual production capacity of 45 million nasal sprays, and is establishing a new USFDA-compliant plant in Indore with 30 million vials capacity. R&D is conducted at a DSIR-approved facility in Pune that has developed 325+ formulations.

Differentiator

Problem solved

Functional benefit

Brands

• SAVAVET: Animal healthcare division of SAVA Healthcare offering companion animal and farm animal pharmaceutical products including Earworks, FELINTRA, ORAPET, and CARODYL
• SAVA Herbals
• Flutiair
• Formezon
• Tiodora
• BIOMIST
• Flutiair-FT
• Momenap

Products and services

• CDMO / Contract Manufacturing Services Contract development and manufacturing services for pharmaceutical companies covering nasal drug delivery, dry powder inhalers, oral solids, and topical formulations. Served clients include Cipla, Dr. Reddy's, and Lupin.
• International Pharmaceutical Export Business Export and distribution of SAVA's pharmaceutical formulations to international markets, leveraging the company's manufacturing capabilities across nasal, inhalation, oral solid, and topical dosage forms.
• SAVAVET Veterinary Pharmaceuticals Veterinary pharmaceutical product range sold through distribution networks to veterinarians and pet owners for animal-health and pet-care use cases.
• SAVA Herbals Consumer Products Herbal personal-care and wellness product range consisting of 30 SKUs, distributed directly to consumers (B2C) following a transition away from earlier B2B distribution.

Quantifiable outcome

• 350+ quality product registrations across 5 continents
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, flagship, strategic and minor.

• Humankind Healthcare Pvt. Ltd., NepalcoreChannel Partner/ Reseller/ Distributor · 24 April 2024Collaboration to launch SAVACORT Dry Powder Inhaler and range of respiratory solutions in Nepal. First Indian drug maker offering respiratory solutions in foreign market. Nepal accounts for 100 deaths per 100,000 every year due to respiratory disease.
• Gulf Maharashtra Business Forum (GMBF) Global and MACCIAflagshipStrategic or Co-development Partner · 24 February 2024SAVA Healthcare hosted MAHABIZ 2024 in collaboration with GMBF Global and Maharashtra Chamber of Commerce, Industry and Agriculture (MACCIA) in Dubai. Two-day business conclave with 700+ entrepreneurs from India, Middle East, Southeast Asia, and Africa. Aligned with India-UAE CEPA signing.
• Dermoscent (Nextmune Group)strategicChannel Partner/ Reseller/ Distributor · 1 January 2024Exclusive partnership in India for distribution of French pet dermo-cosmetic brand Dermoscent under Nextmune Group. Elevates pet wellness offerings in Indian market with premium dermatology products for dogs and cats.
• Symbiosis International UniversityminorStrategic or Co-development Partner · 1 January 2024MoU signed with Symbiosis to drive employee skill development and training programs.
• WATConsultminorGTM or Marketing Partner · 1 January 2021Digital marketing agency appointed for SAVA Herbals new herbal formulation business to drive B2C marketing and e-commerce sales.
• JAMP Pharma CanadacoreChannel Partner/ Reseller/ Distributor · 1 January 2007Long-term business association with JAMP Pharma for distribution of pharmaceutical products in the Canadian market. SAVA exports pharmaceutical products to Canada through this partnership.
• MoviHealth UkrainecoreChannel Partner/ Reseller/ DistributorBusiness association with MoviHealth for distribution of pharmaceutical products in Ukraine and surrounding regions.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Cipla: One of India's largest generic pharma companies with a leading respiratory/inhalation franchise (including Advair generic and other DPIs). It is both an SAVA customer and a direct competitor in the same nasal/DPI product categories.
• Lupin Limited: Major Indian generic pharma manufacturer with a meaningful respiratory and inhalation portfolio. A long-standing SAVA outsourcing partner that also develops and sells competing nasal and DPI products globally.
• Glenmark Pharmaceuticals: Indian pharma major with a focused respiratory franchise (inhalers, nasal sprays) in India and emerging markets. Competes with SAVA's DPI and nasal spray products in overlapping therapeutic categories and geographies.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with a growing respiratory and inhalation portfolio and significant CDMO/export scale. Comparable in terms of generics manufacturing breadth and emerging-market export reach.
• Recipharm: Global CDMO with established inhalation and nasal drug-delivery capabilities serving pharmaceutical customers across regulated markets. A direct comparable to SAVA's CDMO business model and inhalation focus.
• Hovione: Specialty CDMO with deep inhalation and nasal drug-delivery expertise, including particle engineering for DPI formulations. Closely comparable in technical capabilities and CDMO service model.
• Mankind Pharma: Fast-growing Indian pharma company with expanding presence in respiratory and OTC categories. Comparable in domestic Indian market positioning and ambitions in branded generics.

Broad incumbents

• Syngene International: Leading Indian CRO/CDMO providing drug development and manufacturing services to global pharma. Adjacent rather than direct competitor, but a relevant peer for SAVA's CDMO/CRAMS ambitions and scale benchmark.
• Piramal Pharma Solutions: Diversified Indian CDMO offering contract development and manufacturing across multiple dosage forms with global facilities. Comparable in CDMO service breadth and regulated-market compliance focus.

Others

• Aptar Pharma: Global leader in drug-delivery devices including nasal spray pumps and inhalation components. More of an enabling supplier/partner to inhalation and nasal manufacturers like SAVA than a direct competitor, but defines the technology bar.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/savahappinesscommittee
• LinkedInlinkedin.com/company/4616240/admin
• Instagraminstagram.com/sava.healthcare/?utm_source=qr&igshid=MzNlNGNkZWQ4Mg%3D%3D

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAVA Healthcare